TABLE 3.

Diagnostic Performance for Lymph Node Disease in Control and Experimental Arms, Based on Histopathologic Data and Serial PSA Levels During Follow-up

StatisticControl armExperimental armP
Sensitivity17.7 (6.8%–34.5%)65.6% (46.8%–81.4%)0.0002
Specificity96.4% (89.8%–99.3%)75% (64.4%–83.8%)0.0002
Positive LR4.88 (1.29–18.41)2.62 (1.68–4.11)—
Negative LR0.85 (0.73–1.00)0.46 (0.28–0.75)—
PPV66.7% (34.7%–88.3%)*; 74.9% (44.3%–91.9%)†50% (39%–61%)‡; 60.5% (49.4%–70.5%)§0.5884
NPV74.1% (70.9%–77.1%)*; 65.6% (61.9%–69.2%)†85.1% (77.7%–90.4%)‡; 78.9% (69.6%–86%)§0.1091
Accuracy73.5% (64.6%–81.2%)*; 66.5% (57.2%–74.9%)†72.4% (63.3%–80.3%)‡; 71.6% (62.4%–79.5%)§—

  • ↵* Estimated disease prevalence = 29.06%.

  • ↵† Disease prevalence in population = 38.00%.

  • ↵‡ Estimated disease prevalence = 27.59%.

  • ↵§ Disease prevalence in population = 36.80%.

  • LR = likelihood ratio; PPV = positive predictive value; NPV = negative predictive value.

  • Data in parentheses are 95% CIs.